Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer
Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.
Diagnosis & Disease Information
Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer
Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.
Engagement Is Survival: My Take on ASCO 2017
Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.
aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer
An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.
Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy
Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.
Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials
In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team’s study and minority patient representation in breast cancer studies.
Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
Intermittent Letrozole May Benefit Some Patients With Breast Cancer
Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.
FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Pembrolizumab Active in Advanced Gastric Cancer
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...